Pemphigus Vulgaris Market Report 2025

The pemphigus vulgaris market size has grown strongly in recent years. It will grow from $1.8 billion in 2024 to $1.95 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth observed during the historical period can be attributed to factors such as the increasing adoption of biologic therapies, a rising incidence of genetic predisposition, the growing prevalence of pemphigus vulgaris, the expanding role of biosimilars, and improvements in healthcare infrastructure.

The pemphigus vulgaris market size is expected to see strong growth in the next few years. It will grow to $2.63 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. Looking ahead, the growth in the forecast period is expected to be driven by an increase in clinical trials, advancements in precision medicine, the growth of digital health solutions, higher demand for biologics, and the expanded use of telemedicine. Key trends for the forecast period include advancements in biologic therapies, regulatory approvals, the adoption of combination therapies, progress in personalized medicine, and innovations in oral formulations of biologic therapies.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the pemphigus vulgaris market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body's own healthy cells, tissues, or organs. This rise in prevalence is influenced by genetic factors, environmental triggers, and lifestyle changes. Individuals with a family history of autoimmune diseases are more likely to develop them due to inherited vulnerabilities in their immune system. As autoimmune diseases become more widespread, including conditions such as pemphigus vulgaris, there is a greater demand for advanced therapies to manage these disorders. For instance, according to Mayo Clinic Health System in January 2025, the global incidence and prevalence of autoimmune diseases are both increasing, with annual increases estimated at 19.1% and 12.5%, respectively. As a result, the growing prevalence of autoimmune diseases is fueling the expansion of the pemphigus vulgaris market.

Major companies in the pemphigus vulgaris market are investing in solutions aimed at expanding therapeutic options. These investment solutions involve financial strategies and resources allocated to treatment development, research, and market introduction. For example, in January 2023, the Patient Access Network (PAN) Foundation, a U.S.-based non-profit organization, launched a financial assistance program that offers up to $6,600 annually for eligible pemphigus vulgaris patients. This assistance covers deductibles, copays, and coinsurance costs, with eligibility criteria including treatment for pemphigus vulgaris, Medicare insurance that covers necessary medications, and an income at or below 400% of the federal poverty level. The PAN Foundation also provides transportation assistance and connects patients with support organizations.

In December 2023, PAN Foundation partnered with the International Pemphigus & Pemphigoid Foundation to offer financial aid and support to pemphigus vulgaris patients. Through this partnership, the PAN Foundation continues to provide financial assistance of up to $6,600, along with access to educational resources and support services, aiming to alleviate the financial burden of treatment and improve the quality of life for affected individuals. The International Pemphigus and Pemphigoid Foundation is a U.S.-based non-profit organization that provides resources and solutions for pemphigus vulgaris patients.

Major players in the pemphigus vulgaris market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Amgen Inc., Sanofi S.A, Biogen Inc., Genentech, Genmab A/S, argenx SE, Daewoong Pharmaceutical Co. Ltd., HanAll Biopharma Co. Ltd., Artiva Biotherapeutics, Cabaletta Bio Inc., SinoMab BioScience Limited, Topas Therapeutics GmbH, Principia Biopharma Inc., Serpin Pharma LLC, Syntimmune Inc., International Pemphigus & Pemphigoid Foundation.

North America was the largest region in the pemphigus vulgaris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pemphigus vulgaris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pemphigus vulgaris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pemphigus vulgaris is a rare autoimmune disorder that causes blistering and sores on the skin and mucous membranes, including the mouth, throat, and genitals. It occurs when the immune system mistakenly targets the proteins that hold skin cells together, leading to the formation of painful blisters. These blisters can rupture easily, resulting in raw, open sores. Pemphigus vulgaris is a chronic condition and can be life-threatening if not treated properly, usually with immunosuppressive medications to regulate the immune system’s abnormal response.

The primary methods for diagnosing and treating pemphigus vulgaris include clinical evaluation, skin biopsy, and immunological tests to detect autoantibodies. The condition can affect various age groups, including pediatrics, adults, and geriatrics. Treatment is distributed through several channels, including hospitals, retail pharmacies, and online pharmacies. It is used by various end-users such as hospitals, specialty clinics, research institutes, and others.

The pemphigus vulgaris market research report is one of a series of new reports that provides pemphigus vulgaris market statistics, including the pemphigus vulgaris industry global market size, regional shares, competitors with the pemphigus vulgaris market share, detailed pemphigus vulgaris market segments, market trends, and opportunities, and any further data you may need to thrive in the pemphigus vulgaris industry. This pemphigus vulgaris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pemphigus vulgaris market consists of revenues earned by entities by providing services such as physical therapy, palliative care, patient support groups, psychological support and counseling, and immunosuppressive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The pemphigus vulgaris market includes sales of skin biopsy kits and serological test kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.